In contrast to neovascular AMD, which is treated by specific VEGF inhibition, dry AMD has no effective therapy, and their treatment may require a pleiotropic intervention aimed at neuroprotection and modulating RPE survival/apoptosis [29]. The gene discussed is VEGFA; the disease is dry age related macular degeneration.